Clinical Trials | September 11, 2024
Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast
ALS patients experience neuroinflammation and rapid neurodegeneration
ALS patients experience neuroinflammation and rapid neurodegeneration
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
The product is used to treat amyotrophic lateral sclerosis
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Subscribe To Our Newsletter & Stay Updated
